Eiry Roberts - 28 Sep 2026 Form 3 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship
Chief Medical Officer
Issuer ticker
NBIX
Reported as of
28 Sep 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
07 Oct 2026, 18:15:04 UTC
Prior SEC filing
26 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eiry Roberts filed Form 3 for NEUROCRINE BIOSCIENCES INC (NBIX) on 07 Oct 2026.

Key facts

  • This page summarizes Eiry Roberts's Form 3 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
  • 0 reported transactions and 16 derivative rows are listed below.
  • Accepted by SEC: 07 Oct 2026, 18:15.

Change

  • Previous filing in this sequence was filed on 26 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727606 Primary reporting owner

ROBERTS EIRY

Relationship
Chief Medical Officer
Address
6027 EDGEWOOD BEND CT., SAN DIEGO
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Signature date
07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
51,331
Date
28 Sep 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,147
Exercise price
$102.90
Footnotes
F2
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
48,199
Exercise price
$117.63
Footnotes
F3
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
60,005
Exercise price
$79.02
Footnotes
F4
NBIX holding Derivative

Incentive Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
965
Exercise price
$103.52
Footnotes
F5
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
51,567
Exercise price
$103.52
Footnotes
F5
NBIX holding Derivative

Incentive Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
747
Exercise price
$133.84
Footnotes
F6
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
21,782
Exercise price
$133.84
Footnotes
F6
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
27,770
Exercise price
$136.69
Footnotes
F7
NBIX holding Derivative

Incentive Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
853
Exercise price
$117.18
Footnotes
F8
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,408
Exercise price
$117.18
Footnotes
F8
NBIX holding Derivative

Non-Qualified Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,087
Exercise price
$124.12
Footnotes
F9
NBIX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,114
Exercise price
Footnotes
F10, F11
NBIX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,242
Exercise price
Footnotes
F11, F12
NBIX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,743
Exercise price
Footnotes
F11, F13
NBIX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,081
Exercise price
Footnotes
F11, F14
NBIX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,949
Exercise price
Footnotes
F11, F15
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 15 footnotes

Footnote F1

50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Footnote F2

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

Footnote F3

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

Footnote F4

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

Footnote F5

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F6

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F7

Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.

Footnote F8

Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F9

Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F10

Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.

Footnote F11

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F12

Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.

Footnote F13

Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.

Footnote F14

Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.

Footnote F15

Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .